XBI - ETF AI Analysis
Top Page
SPDR S&P BIOTECH ETF (XBI)
Rating:58Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown strong gains so far this year and over the past month, indicating positive recent momentum in its holdings.
Broad Biotech Diversification
With many holdings and each top position making up only a small slice of the fund, investors are not overly reliant on any single biotech stock.
Healthy Asset Base
The fund manages a large pool of assets, which can support liquidity and trading efficiency for investors.
Negative Factors
Highly Concentrated in Biotech
Almost all of the ETF’s exposure is in the health care sector, so its performance is heavily tied to the ups and downs of biotech stocks.
Limited Geographic Diversification
The fund is almost entirely invested in U.S. companies, offering little exposure to biotech opportunities in other regions.
Mixed Performance Among Top Holdings
While several leading positions have delivered strong gains, at least one notable holding has shown weak performance, which can drag on overall returns.
XBI vs. SPDR S&P 500 ETF (SPY)
AUM8.23B
RegionNorth America
Expense Ratio0.35%
Beta1.03
IssuerSPDR
Inception DateJan 31, 2006
Dividend Yield0.33%
Asset ClassEquity
Index TrackedS&P Biotechnology Select Industry
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume9,036,193
30 Day Avg. Volume8,868,311
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
210.98Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering143
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
XBI Summary
The SPDR S&P Biotech ETF (XBI) is a fund that tracks the S&P Biotechnology Select Industry Index, giving you broad exposure to U.S. biotech companies in the health care sector. It holds many different biotech firms, from more established names like Alkermes to fast-growing innovators such as Twist Bioscience, all with similar-sized weights so no single company dominates. Someone might invest in XBI if they believe in the long-term growth of new drugs, gene therapies, and medical breakthroughs, and want diversification across many biotech stocks. A key risk is that biotech shares can be very volatile and may rise or fall sharply with drug trial news and market sentiment.
How much will it cost me?The SPDR S&P Biotech ETF (XBI) has an expense ratio of 0.35%, meaning you’ll pay $3.50 per year for every $1,000 invested. This expense ratio is slightly higher than average because the fund is actively managed with an equal-weighted structure, which requires more frequent adjustments compared to passively managed ETFs.
What would affect this ETF?The SPDR S&P Biotech ETF (XBI) could benefit from advancements in biotechnology, such as breakthroughs in gene editing and personalized medicine, which drive innovation and growth in the sector. However, it may face challenges from regulatory hurdles, high research costs, and potential economic downturns that could impact funding and investor sentiment in the biotech industry.
XBI Top 10 Holdings
XBI is a pure-play U.S. biotech fund, and its story is all about drug developers on the move rather than broad market giants. Names like TG Therapeutics, Travere Therapeutics, and Alkermes have been rising, giving the ETF a helpful tailwind, while Revolution Medicines and Twist Bioscience remain more of a mixed bag, with promising pipelines but still-strained finances. Krystal Biotech and Exelixis add some steadier strength, but overall the fund leans heavily on volatile, early- and mid-stage biotechs, making performance highly sensitive to trial results and FDA news rather than the broader economy.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| TG Therapeutics | 1.99% | $161.66M | $7.36B | 37.52% | 65 Neutral | |
| Travere Therapeutics | 1.92% | $155.98M | $4.55B | 258.90% | 56 Neutral | |
| Alkermes | 1.88% | $152.65M | $7.49B | 48.44% | 80 Outperform | |
| Twist Bioscience | 1.84% | $149.13M | $4.61B | 127.24% | 43 Neutral | |
| Revolution Medicines | 1.74% | $141.42M | $31.73B | 279.08% | 52 Neutral | |
| Exelixis | 1.49% | $120.94M | $13.45B | 27.75% | 78 Outperform | |
| Arrowhead Pharmaceuticals | 1.49% | $120.87M | $10.48B | 373.44% | 57 Neutral | |
| Krystal Biotech | 1.47% | $119.01M | $9.48B | 131.98% | 80 Outperform | |
| Neurocrine | 1.46% | $118.54M | $16.36B | 28.43% | 80 Outperform | |
| Nuvalent | 1.43% | $116.45M | $9.75B | 57.53% | 43 Neutral |
XBI Technical Analysis
Positive
―
Price Trends
132.70
Positive
128.92
Positive
119.82
Positive
Market Momentum
-0.23
Negative
53.20
Neutral
53.98
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For XBI, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 131.51, equal to the 50-day MA of 132.70, and equal to the 200-day MA of 119.82, indicating a bullish trend. The MACD of -0.23 indicates Negative momentum. The RSI at 53.20 is Neutral, neither overbought nor oversold. The STOCH value of 53.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XBI.
XBI Peer Comparison
Comparison Results
Performance Comparison
XBI
SPDR S&P BIOTECH ETF
136.40
54.60
66.75%
IBB
iShares Biotechnology ETF
―
―
―
IYH
iShares U.S. Healthcare ETF
―
―
―
IHI
iShares U.S. Medical Devices ETF
―
―
―
FHLC
Fidelity MSCI Health Care Index ETF
―
―
―
FBT
First Trust NYSE Arca Biotechnology Index Fund
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents